SCHEMBL3083948

SCHEMBL3083948

CCN(C(=O)C(Cc1ccc([N+](=O)[O-])cc1)C(=O)NS(=O)(=O)/C=C/c1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PTPN1 P18031 1/20 0.40
CDC25B P30305 1/20 0.40
DUSP3 P51452 1/20 0.40
POLB P06746 1/20 0.39
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
LMNA P02545 1/20 0.36
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083952 1.00 MAPT (0.44) MAPTTRPM8ALDH1A1MEN1KMT2A
SCHEMBL3084446 0.91 TRPM8 (0.43) MAPTTRPM8ALDH1A1MEN1KMT2A
SCHEMBL3084443 0.91 TRPM8 (0.43) MAPTTRPM8ALDH1A1MEN1KMT2A
SCHEMBL15000182 0.90 MAPT (0.44) MAPTMEN1KMT2APTPN1CDC25B
SCHEMBL15000184 0.90 MAPT (0.44) MAPTMEN1KMT2APTPN1CDC25B
SCHEMBL3096530 0.87 ALDH1A1 (0.40) MAPTTRPM8ALDH1A1MEN1KMT2A
SCHEMBL3096541 0.87 ALDH1A1 (0.40) MAPTTRPM8ALDH1A1MEN1KMT2A
SCHEMBL3100158 0.87 KMT2A (0.41) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL3100420 0.87 POLB (0.41) TRPM8ALDH1A1MEN1KMT2APOLB
SCHEMBL3100152 0.87 KMT2A (0.41) ALDH1A1MEN1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MAPT 2813/4885TRPM8 135/4885ALDH1A1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.